BEP(500)

Phase 3Small molecule

IInstitute of Cancer Research, United Kingdom

BEP(500) is one of 5 small molecule programs targeting Seminoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SeminomaActive, not recruiting

SeminomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Seminoma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

4 2

Jevtana

Sanofi

Phase 2

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

2 4

Vepesid

AAvyxa

Phase 2

2 5

BEP(500)

IInstitute of Cancer Research, United Kingdom

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seminoma1 trial

Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

Completed·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT01726374·246 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BEP(500). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BEP(500) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BEP(500). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Cancer Research, United Kingdom company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitute of Cancer Research, United Kingdom

BEP(500)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seminoma1 trial

References

Drug Info

Quick Facts

Related News